Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis
What this study shows
Quantitative phosphoproteomics show mTORC1 activates de novo pyrimidine synthesis.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Mammalian cells) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Mammalian cells |
| Journal | Science |
| Year | 2013 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1126/science.1228771 · PMID 23429704 |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Quantitative phosphoproteomics |
| Target | mTORC1 / S6K1 / CAD |
| Model | Mammalian cells |
| Effect | mTORC1 activates de novo pyrimidine synthesis (CAD phosphorylation), among 335 mTOR-controlled phosphosites |
In the Atlas
Related topics
Links in the pathway map
- Supports S6K1 activates Nucleotide synthesis
More studies on this topic
- ERK2 phosphorylates PFAS to mediate posttranslational control of de novo purine synthesis (2020)
- The mTORC1-SLC4A7 axis stimulates bicarbonate import to enhance de novo nucleotide synthesis (2022)
- Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1 (2013)
- mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle (2016)
Was this page useful?
Thank you. Your answer was counted anonymously.